Bivatuzumab (formerly BIWA 4) is a humanized monoclonal antibody against CD44 v6. The DrugMonitor™ Anti-Bivatuzumab Antibody (VS-1224-YC205) is an anti-drug antibody (ADA) against Bivatuzumab. This drug-based antibody is raised in mice immunized with the Bivatuzumab. The anti-Bivatuzumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Bivatuzumab in samples.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Anti-CD44 Recombinant Antibody (Bivatuzumab)Recombinant humanized (from mouse) antibody expressed in CHO binding to human CD44. Bivatuzumab is a humanized monoclonal antibody against CD44 v6. It has been chemically linked to various radioisotopes for use in radiotherapy for, e.g. inoperable recurrent or metastatic head and neck cancer. It has also been linked to a cytotoxic drug mertansine to form bivatuzumab mertansine.
Afuco™ Anti-CD44 ADCC Recombinant Antibody (Bivatuzumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human CD44. Bivatuzumab is a humanized monoclonal antibody against CD44 v6.
There are currently no Customer reviews or questions for VS-1224-YC205. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.